PuSH - Publikationsserver des Helmholtz Zentrums München

Subklewe, M. ; Geiger, C. ; Lichtenegger, F.S. ; Javorovic, M. ; Kvalheim, G.* ; Schendel, D.J. ; Bigalke, I.

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.

Cancer Immunol. Immunother. 63, 1093-1103 (2014)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Dendritic cell (DC)-based immunotherapy is a promising strategy for the elimination of minimal residual disease in patients with acute myeloid leukemia (AML). Particularly, patients with a high risk of relapse who are not eligible for hematopoietic stem cell transplantation could benefit from such a therapeutic approach. Here, we review our extensive studies on the development of a protocol for the generation of DCs with improved immunogenicity and optimized for the use in cell-based immunotherapy. This new generation DC vaccine combines the production of DCs in only 3 days with Toll-like receptor-signaling-induced cell maturation. These mature DCs are then loaded with RNA encoding the leukemia-associated antigens Wilm's tumor protein 1 and preferentially expressed antigen in melanoma in order to stimulate an AML-specific T-cell-based immune response. In vitro as well as in vivo studies demonstrated the enhanced capacity of these improved DCs for the induction of tumor-specific immune responses. Finally, a proof-of-concept Phase I/II clinical trial is discussed for post-remission AML patients with high risk for disease relapse.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Aml ; Cancer Immunotherapy ; Clinical Trial ; Dendritic Cells ; Pivac 13 ; Vaccine; Minimal Residual Disease; Acute Lymphoblastic-leukemia; Wt1 Peptide Vaccination; Cd8(+) T-cells; Complete Remission; Prognostic Impact; Gene-expression; Flow-cytometry; Tumor Lysate; Cancer
ISSN (print) / ISBN 0340-7004
e-ISSN 1432-0851
Zeitschrift Cancer Immunology, Immunotherapy
Quellenangaben Band: 63, Heft: 10, Seiten: 1093-1103 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Molecular Immunology (IMI)
CCG Hematopoetic Cell Transplants (IMI-KHZ)